Global Cancer Biomarker Market Revenue Grows at a CAGR of 12.8%

Introduction

Straits Research released its highly anticipated report, “Cancer Biomarker Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 38.5 billion in 2025 and is projected to expand to USD 120 billion by 2034 registering a compound annual growth rate (CAGR) of 12.8%.

Market Dynamics

Technological advancements in biomarker discovery are transforming the cancer diagnostics landscape by leveraging AI, machine learning, and big data analytics to rapidly analyze genomic, proteomic, and metabolomic data, enabling the identification of highly sensitive and specific biomarkers. Automated workflows and advanced bioinformatics tools integrate multi-omics datasets, improving patient stratification, predictive modeling, and personalized treatment strategies. Alongside this, the rise of liquid biopsy has emerged as a key trend, offering non-invasive methods such as circulating tumor DNA, circulating tumor cells, and exosomes for early cancer detection, real-time treatment monitoring, and relapse prediction. These approaches reduce reliance on invasive tissue biopsies and align closely with precision medicine. The market is strongly driven by the rising global burden of cancer, fueled by aging populations, lifestyle factors, and environmental exposures, which increases demand for early and accurate diagnostic solutions. Cancer biomarkers play a critical role in improving survival rates by enabling timely and targeted interventions, making them essential in modern oncology. However, market growth is restrained by the high cost and complexity of biomarker discovery and validation, which require extensive research, multi-stage clinical trials, advanced sequencing infrastructure, and compliance with stringent regulatory frameworks. Despite these challenges, growing investment in R&D presents a significant opportunity, as increased funding from governments, pharmaceutical companies, and private investors accelerates innovation in genomic profiling, liquid biopsy platforms, and AI-driven diagnostics, fostering collaborations and strengthening global adoption of biomarker-based cancer solutions.

Key Highlights

• By Cancer type: The breast cancer segment held a significant market share of 25.3% in 2025.
• By Application: The personalized medicine segment is the fastest growing segment during the forecast period at a CAGR of 13.6%.
• By Region: North America dominated the global market with the largest market share of 45.6% in 2025.

Competitive Players

1. Hoffmann-La Roche Ltd.
2. Thermo Fisher Scientific Inc.
3. Illumina, Inc.
4. QIAGEN N.V.
5. Abbott Laboratories
6. Bio-Rad Laboratories, Inc.
7. Agilent Technologies, Inc.
8. bioMérieux SA
9. Becton, Dickinson and Company (BD)
10. Myriad Genetics, Inc.

Recent Developments

• In 2025, Myriad Genetics, Inc. (US) collaborated with Gabbi (US), a telehealth solution for breast cancer risk assessment & specialist care services. The companies will collaborate to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk with RiskScore Hereditary Cancer Test.

Segmentation

1. By Cancer Type (2026-2034)
   1. Lung Cancer
   2. Prostate Cancer
   3. Melanoma
   4. Thyroid Cancer
   5. Kidney Cancer
   6. Bladder Cancer
   7. Leukemia
   8. Non-Hodgkin's lymphoma
   9. Colorectal Cancer
   10. Breast Cancer
   11. Other Cancer Types
2. By Application (2026-2034)
   1. Personalized Medicines
   2. Drug Discovery & Development
   3. Diagnostics
   4. Other Applications
3. By Region (2026-2034)
   1. North America
   2. Europe
   3. Asia Pacific
   4. Middle East & Africa
   5. Latin America